RS64332B1 - Neuroaktivni steroidi, kompozicije i njihova upotreba - Google Patents
Neuroaktivni steroidi, kompozicije i njihova upotrebaInfo
- Publication number
- RS64332B1 RS64332B1 RS20230525A RSP20230525A RS64332B1 RS 64332 B1 RS64332 B1 RS 64332B1 RS 20230525 A RS20230525 A RS 20230525A RS P20230525 A RSP20230525 A RS P20230525A RS 64332 B1 RS64332 B1 RS 64332B1
- Authority
- RS
- Serbia
- Prior art keywords
- substituted
- compound
- unsubstituted
- mmol
- group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
- C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0029—Ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/003—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring the S atom directly linked to a ring carbon atom of the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C07J41/0011—Unsubstituted amino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
- C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J75/00—Processes for the preparation of steroids in general
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161532427P | 2011-09-08 | 2011-09-08 | |
| PCT/US2012/054261 WO2013036835A1 (en) | 2011-09-08 | 2012-09-07 | Neuroactive steroids, compositions, and uses thereof |
| EP12766766.5A EP2753632B1 (en) | 2011-09-08 | 2012-09-07 | Neuroactive steroids, compositions, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS64332B1 true RS64332B1 (sr) | 2023-08-31 |
Family
ID=46964032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20230525A RS64332B1 (sr) | 2011-09-08 | 2012-09-07 | Neuroaktivni steroidi, kompozicije i njihova upotreba |
Country Status (20)
| Country | Link |
|---|---|
| US (5) | US20150158903A1 (enExample) |
| EP (2) | EP4245369A3 (enExample) |
| JP (6) | JP6205362B2 (enExample) |
| CN (4) | CN113956315B (enExample) |
| AU (6) | AU2012304412A1 (enExample) |
| BR (1) | BR112014005373B1 (enExample) |
| CA (1) | CA2848212C (enExample) |
| DK (1) | DK2753632T3 (enExample) |
| ES (1) | ES2951664T3 (enExample) |
| FI (1) | FI2753632T3 (enExample) |
| HR (1) | HRP20230747T1 (enExample) |
| HU (1) | HUE062616T2 (enExample) |
| LT (1) | LT2753632T (enExample) |
| PL (1) | PL2753632T3 (enExample) |
| PT (1) | PT2753632T (enExample) |
| RS (1) | RS64332B1 (enExample) |
| RU (1) | RU2665571C2 (enExample) |
| SI (1) | SI2753632T1 (enExample) |
| SM (1) | SMT202300232T1 (enExample) |
| WO (1) | WO2013036835A1 (enExample) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006047022A1 (en) | 2004-10-25 | 2006-05-04 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis |
| KR101415329B1 (ko) | 2005-11-28 | 2014-07-04 | 마리누스 파마슈티컬스 | ｇａｎａｘｏｌｏｎｅ 제형, 이의 제조방법 및 용도 |
| US9034859B2 (en) | 2011-04-06 | 2015-05-19 | Virginia Commonwealth University | Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation |
| EP4245369A3 (en) * | 2011-09-08 | 2023-11-22 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US10478505B2 (en) | 2011-09-23 | 2019-11-19 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| AU2012323888A1 (en) | 2011-10-14 | 2014-05-29 | Sage Therapeutics, Inc. | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| AU2013212287B2 (en) | 2012-01-23 | 2017-11-23 | Sage Therapeutics, Inc. | Neuroactive steroid formulations and methods of treating CNS disorders |
| WO2014028398A2 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| IL304912A (en) | 2012-08-21 | 2023-10-01 | Sage Therapeutics Inc | Treatment methods for epilepsy and status epilepticus |
| EP4335505A3 (en) | 2012-11-30 | 2024-06-05 | The Regents of The University of California | Anticonvulsant activity of steroids |
| MX362544B (es) * | 2013-03-13 | 2019-01-24 | Sage Therapeutics Inc | Esteroides neuroactivos y metodos para su uso. |
| EP3865135A3 (en) * | 2013-03-13 | 2021-11-03 | Sage Therapeutics, Inc. | Neuroactive steroids for use in therapy |
| TR201901745T4 (tr) * | 2013-04-17 | 2019-03-21 | Sage Therapeutics Inc | 19-nor C3,3-disübstitüe edilmiş C21- n-pirazolil steroidleri ve bunların kullanım yöntemleri. |
| WO2014169836A1 (en) * | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| EP2986624B1 (en) | 2013-04-17 | 2020-03-25 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids for methods of treatment |
| CN103333216A (zh) * | 2013-06-04 | 2013-10-02 | 苏州大学 | 5α-6-酮-胆甾烷类似物及其应用 |
| RU2754534C2 (ru) | 2013-07-19 | 2021-09-03 | Сейдж Терапьютикс, Инк. | Нейроактивные стероиды, композиции и их использование |
| CA3235088A1 (en) | 2013-08-23 | 2015-02-26 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| DK3086793T3 (da) | 2013-12-24 | 2022-08-01 | Univ Virginia Commonwealth | Anvendelse af oxygenerede cholesterolsulfater (ocs) til behandling af nyredysfunktion |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JP6628745B2 (ja) * | 2014-06-18 | 2020-01-15 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびその使用方法 |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| BR112017007053A2 (pt) * | 2014-10-07 | 2018-06-19 | Sage Therapeutics Inc | compostos neuroativos e métodos de utilização deste composto. |
| TW202426002A (zh) | 2014-10-16 | 2024-07-01 | 美商賽吉醫療公司 | 用於治療中樞神經系統(cns)病症之組合物及方法 |
| EP3753927B1 (en) | 2014-10-16 | 2023-07-19 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| LT3224269T (lt) | 2014-11-27 | 2020-07-10 | Sage Therapeutics, Inc. | Kompozicijos ir būdai, skirti cns sutrikimams gydyti |
| HUE054092T2 (hu) | 2015-01-26 | 2021-08-30 | Sage Therapeutics Inc | Központi idegrendszeri zavarok kezelésére szolgáló kompozíciók és eljárások |
| WO2016134301A2 (en) | 2015-02-20 | 2016-08-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2017007832A1 (en) * | 2015-07-06 | 2017-01-12 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| SI3812392T1 (sl) * | 2015-07-06 | 2025-09-30 | Sage Therapeutics, Inc. | Oksisteroli in postopki za uporabo le-teh |
| MA42410B1 (fr) * | 2015-07-06 | 2021-04-30 | Sage Therapeutics Inc | Oxystérols et leurs méthodes d'utilisation |
| MX2018001145A (es) * | 2015-07-30 | 2018-06-15 | Intercept Pharmaceuticals Inc | Métodos para la preparación de ácidos biliares y derivados de los mismos. |
| ES2910425T3 (es) | 2015-09-17 | 2022-05-12 | Modernatx Inc | Compuestos y composiciones para la administración intracelular de agentes terapéuticos |
| EA036155B1 (ru) | 2015-10-16 | 2020-10-06 | Маринус Фармасьютикалс, Инк. | Инъекционные составы нейростероида, содержащие наночастицы |
| US9637514B1 (en) | 2015-10-26 | 2017-05-02 | MAX BioPharma, Inc. | Oxysterols and hedgehog signaling |
| DK3394030T3 (da) | 2015-12-22 | 2022-03-28 | Modernatx Inc | Forbindelser og sammensætninger til intracellulær afgivelse af midler |
| US20190047939A1 (en) * | 2016-03-02 | 2019-02-14 | Patheon Austria Gmbh & Co Kg | Process and intermediates for the production of 17(20)-ene b-seco steroids |
| HK1258616A1 (zh) * | 2016-03-08 | 2019-11-15 | Sage Therapeutics, Inc. | 神经活性类固醇、组合物、及其用途 |
| HUE059491T2 (hu) * | 2016-04-01 | 2022-11-28 | Sage Therapeutics Inc | Oxiszterolok és azok alkalmazási eljárásai |
| WO2017193046A1 (en) * | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| PT3481846T (pt) * | 2016-07-07 | 2021-08-13 | Sage Therapeutics Inc | 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda |
| WO2018013615A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| DK3481845T3 (da) | 2016-07-11 | 2023-11-27 | Sage Therapeutics Inc | C17, c20 og c21 substituerede neuroaktive steroider og deres anvendelsesmetoder |
| MX2019001323A (es) | 2016-08-02 | 2019-07-04 | Univ Virginia Commonwealth | Composiciones que comprenden 3-sulfato de 5-colesteno-3, 25-diol (25hc3s), o una sal farmaceuticamente aceptable del mismo, y por lo menos un oligosacarido ciclico. |
| EP3481387A4 (en) | 2016-08-11 | 2020-04-08 | Ovid Therapeutics Inc | METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| EP3519422B1 (en) * | 2016-09-30 | 2022-08-31 | Sage Therapeutics, Inc. | C7 substituted oxysterols and these compounds for use as nmda modulators |
| MA46566A (fr) * | 2016-10-18 | 2019-08-28 | Sage Therapeutics Inc | Oxystérols et leurs procédés d'utilisation |
| EP4105223B1 (en) * | 2016-10-18 | 2025-04-30 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| WO2018089540A1 (en) | 2016-11-08 | 2018-05-17 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| LT3596041T (lt) | 2017-03-15 | 2023-01-25 | Modernatx, Inc. | Terapinių medžiagų, skirtų intraląsteliniam tiekimui, junginys ir sudėtys |
| ES3020935T3 (en) | 2017-03-15 | 2025-05-23 | Modernatx Inc | Lipid nanoparticle formulation |
| US11203569B2 (en) | 2017-03-15 | 2021-12-21 | Modernatx, Inc. | Crystal forms of amino lipids |
| US12077501B2 (en) | 2017-06-14 | 2024-09-03 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| CN109280069B (zh) * | 2017-07-19 | 2020-09-04 | 青岛海洋生物医药研究院股份有限公司 | 3β-羟基-麦角甾-5-烯甾类衍生物及其药物用途 |
| WO2019025250A1 (en) | 2017-08-04 | 2019-02-07 | Basf Se | SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI |
| IT201700100483A1 (it) * | 2017-09-07 | 2019-03-07 | Dipharma Francis Srl | Ossidazione selettiva dell’acido iodesossicolico |
| AU2019314405A1 (en) * | 2018-07-31 | 2021-03-18 | Chisholm, John D. | Methods of activating microglial cells |
| JP2022501348A (ja) * | 2018-09-19 | 2022-01-06 | モデルナティエックス インコーポレイテッドModernaTX, Inc. | ステロール類似体及びその使用 |
| EP3853202A1 (en) | 2018-09-19 | 2021-07-28 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
| BR112021013393A2 (pt) | 2019-01-08 | 2021-09-14 | Chengdu Kanghong Pharmaceutical Co, Ltd. | Composto de esteroide e uso do mesmo e método de preparação para o mesmo |
| CN114206900A (zh) | 2019-05-31 | 2022-03-18 | 萨奇治疗股份有限公司 | 神经活性类固醇及其组合物 |
| MX2021015942A (es) * | 2019-06-27 | 2022-04-18 | Sage Therapeutics Inc | Composiciones y métodos para tratar trastornos del snc. |
| WO2021026124A1 (en) | 2019-08-05 | 2021-02-11 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treatment of status epilepticus |
| BR112022004759A2 (pt) | 2019-09-19 | 2022-06-21 | Modernatx Inc | Composições e compostos lipídicos com cauda ramificada para entrega intracelular de agentes terapêuticos |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| KR20220134529A (ko) | 2019-12-06 | 2022-10-05 | 마리누스 파마슈티컬스 인코포레이티드 | 복합 결절성 경화증의 치료에 사용하기 위한 가낙솔론 |
| CN113387991B (zh) * | 2020-03-13 | 2024-06-18 | 苏州朗科生物技术股份有限公司 | 一种合成地屈孕酮的方法及化合物 |
| US20240239835A9 (en) * | 2020-03-18 | 2024-07-18 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| CZ309819B6 (cs) * | 2020-10-23 | 2023-11-08 | Univerzita Palackého v Olomouci | Sterolové deriváty, přípravky obsahující tyto deriváty a jejich použití |
| CN112679571A (zh) * | 2020-12-24 | 2021-04-20 | 广西壮族自治区中国科学院广西植物研究所 | 一种罗汉果醇衍生物单体、其制备方法及应用 |
| CA3223179A1 (en) | 2021-06-11 | 2022-12-15 | Sage Therapeutics, Inc. | Neuroactive steroid for the treatment of alzheimer's disease |
| JP2024534558A (ja) | 2021-09-22 | 2024-09-20 | セージ セラピューティクス， インコーポレイテッド | 重水素化ｎｍｄａ正調節化合物及びその使用方法 |
| KR102749670B1 (ko) * | 2021-09-28 | 2025-01-03 | 경희대학교 산학협력단 | 신규한 콜린산 유도체 및 이의 용도 |
| WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
| CN115624555A (zh) * | 2022-02-24 | 2023-01-20 | 中国药科大学 | 猪去氧胆酸在制备抗抑郁药物中的应用 |
| US12454547B2 (en) | 2022-04-22 | 2025-10-28 | Asteroid Therapeutics | Steroidal compositions and methods of treating lipogenic cancers |
| TW202430133A (zh) * | 2022-11-21 | 2024-08-01 | 美商賽吉醫療公司 | 負ｎｍｄａ調節化合物及其使用方法 |
Family Cites Families (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2259698A (en) | 1938-05-07 | 1941-10-21 | Rare Chemicals Inc | Physiologically effective substance and process of preparing same |
| US2594323A (en) * | 1948-07-22 | 1952-04-29 | Upjohn Co | 24-substituted delta 5-cholene-3, 24-diols |
| US2673206A (en) | 1950-06-07 | 1954-03-23 | Schering Corp | 25-ethinyl steroids |
| US3079385A (en) * | 1961-01-24 | 1963-02-26 | Roussel Uclaf | Novel process of preparation of polyhydroxylated pregnanes |
| US3206459A (en) | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
| GB1120870A (en) | 1966-07-11 | 1968-07-24 | Ici Ltd | Quinoline derivatives |
| JPS5324071B2 (enExample) | 1974-04-30 | 1978-07-18 | ||
| US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| CH628907A5 (en) | 1975-10-10 | 1982-03-31 | Hoffmann La Roche | Process for the preparation of 24,25-dihydroxycholesterol derivatives |
| JPS5840960B2 (ja) | 1976-12-28 | 1983-09-08 | 帝人株式会社 | ヒドロキシコレステロ−ル立体異性体間の相互変換法 |
| US4183852A (en) | 1977-07-18 | 1980-01-15 | Kaiser Emil T | Process for preparing 25-hydroxycholesterol |
| JPS54163565A (en) | 1978-06-09 | 1979-12-26 | Teijin Ltd | 24*255epoxyy3beta * 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production |
| US4174345A (en) | 1978-08-01 | 1979-11-13 | Kaiser Emil T | Synthesis of steroids |
| US4269777A (en) | 1979-05-21 | 1981-05-26 | Wisconsin Alumni Research Foundation | Isotopically labeled vitamin D derivatives and processes for preparing same |
| JPS5735597A (en) | 1980-08-13 | 1982-02-26 | Teijin Ltd | 25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation |
| US4358406A (en) * | 1981-07-27 | 1982-11-09 | Wisconsin Alumni Research Foundation | 26,26,26,27,27,27-Hexafluoro-1α,25-dihydroxycholecalciferol and process for preparing same |
| JPS61254599A (ja) | 1985-05-07 | 1986-11-12 | Sumitomo Pharmaceut Co Ltd | コレステロ−ルのフツ素誘導体 |
| JPS6253960A (ja) | 1985-05-30 | 1987-03-09 | Taisho Pharmaceut Co Ltd | ビタミンｄ↓３の誘導体 |
| JPS62187485A (ja) | 1986-02-13 | 1987-08-15 | Teijin Ltd | ２４，２５−エポキシコレステロ−ル類の製造法 |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| JPH03500049A (ja) * | 1987-08-25 | 1991-01-10 | ジー、ケルビン・ダブリュー | ストレス、不安および発作活性の緩和のための組成物および方法 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| JP4008024B2 (ja) | 1993-05-24 | 2007-11-14 | パーデュー、ファーマ、リミテッド、パートナーシップ | Ｇａｂａａレセプター複合体と相互作用させるための化合物 |
| IL110309A0 (en) | 1993-07-15 | 1994-10-21 | Univ Kentucky Res Found | A method of protecting against neuron loss |
| DE4338316A1 (de) | 1993-11-10 | 1995-05-11 | Jenapharm Gmbh | Neue Steroide mit radikophilen Substituenten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| KR100338287B1 (ko) | 1994-02-14 | 2002-11-30 | 푸르듀 파머 리미티드 | 감마-아미노부티르산a수용체의알로오스테리조절용안드로스탄및프레그난 |
| IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
| US5595996A (en) * | 1994-10-25 | 1997-01-21 | Merck & Co., Inc. | 7-substituted 4-aza cholanic acid derivatives and their use |
| GEP20002033B (en) * | 1994-11-23 | 2000-04-10 | Cocensys Inc Us | Androstane and Pregnane Series Compounds for Allosteric Modulation of GABA Receptor |
| JPH08268917A (ja) * | 1995-03-31 | 1996-10-15 | D D S Kenkyusho:Kk | 癌組織への移行性の高い制癌剤 |
| ES2235187T3 (es) * | 1995-06-06 | 2005-07-01 | Euro-Celtique S.A. | Esteroides neuroactivos de las series del androstano y el pregnano. |
| US5792635A (en) | 1995-06-07 | 1998-08-11 | Magainin Pharmaceuticals, Inc. | Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine |
| US6645953B2 (en) | 1995-06-23 | 2003-11-11 | Novo Nordisk A/S | Meiosis regulating compounds |
| WO1997000884A1 (en) | 1995-06-23 | 1997-01-09 | Novo Nordisk A/S | Meiosis regulating compounds |
| JP4313435B2 (ja) | 1995-07-24 | 2009-08-12 | トラスティーズ オブ ボストン ユニバーシティー | プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制 |
| US5888996A (en) | 1995-07-26 | 1999-03-30 | Trustees Of Boston University | Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity |
| WO1997042215A1 (en) | 1996-05-06 | 1997-11-13 | Bionumerik Pharmaceuticals, Inc. | Process for preparing 27-hydroxy cholesterol and related derivatives |
| JPH09328498A (ja) | 1996-06-10 | 1997-12-22 | Teijin Ltd | ２４，２５−ジヒドロキシコレステロールの製造法およびその合成中間体 |
| AU3967297A (en) * | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| DE19635525A1 (de) | 1996-08-20 | 1998-02-26 | Schering Ag | 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
| US6122371A (en) | 1997-07-22 | 2000-09-19 | Atwell; Ronald C. | Apparatus for protecting coin-operated telephones from vandalism and larceny |
| EP1077933A1 (en) | 1998-05-11 | 2001-02-28 | Novo Nordisk A/S | Substituted guanidines and diaminonitroethenes, their preparation and use |
| KR20010043558A (ko) | 1998-05-13 | 2001-05-25 | 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 | 감수분열 조절 화합물 |
| US8541600B2 (en) | 1998-11-24 | 2013-09-24 | Harbor Therapeutics, Inc. | 11-aza, 11-thia and 11-oxa sterol compounds and compositions |
| DE19917930A1 (de) | 1999-04-15 | 2000-10-19 | Schering Ag | Ent-Steroide als selektiv wirksame Estrogene |
| IL146230A0 (en) | 1999-04-29 | 2002-07-25 | Purdue Pharma Ltd | 3α-HYDROXY-3β-METHOXYMETHYL-SUBSTITUTED STEROIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
| GB9910934D0 (en) * | 1999-05-11 | 1999-07-14 | Res Inst Medicine Chem | Chemical compounds |
| CN1111167C (zh) | 1999-10-22 | 2003-06-11 | 中国科学院上海有机化学研究所 | 3β－羟基－5－胆烯酸酯类衍生物、合成方法及其用途 |
| CN1098273C (zh) | 1999-11-12 | 2003-01-08 | 中国科学院上海有机化学研究所 | 高立体选择性的合成24r,25－和24s,25－二羟基甾体化合物 |
| GB0000228D0 (en) | 2000-01-06 | 2000-03-01 | Phytopharm Plc | Fluoro substituted sapogenins and their use |
| GB0019290D0 (en) | 2000-08-04 | 2000-09-27 | Symphar Sa | Methods for inducing apolipoprotein E secretion |
| GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| GB0107822D0 (en) | 2001-03-28 | 2001-05-23 | Phytopharm Plc | Sapogenin derivatives their synthesis and use methods based upon their use |
| WO2002090375A2 (en) | 2001-05-03 | 2002-11-14 | The University Of Chicago | Liver x receptor agonists |
| US20070197484A1 (en) | 2001-05-03 | 2007-08-23 | Ching Song | Method of treating disorder related to high cholesterol concentration |
| EP1450816A4 (en) * | 2001-11-08 | 2008-02-13 | Univ Chicago | METHOD OF TREATING DISORDERS RELATED TO HIGH CHOLESTEROL RATE |
| CA2468989A1 (en) | 2001-12-07 | 2003-06-19 | Daniel M. Schwartz | Treatment for age-related macular degeneration |
| WO2003082893A2 (en) | 2002-03-27 | 2003-10-09 | Phytopharm Plc | Theraputic methods and uses of sapogenins and their derivatives |
| CN102727501A (zh) | 2002-03-27 | 2012-10-17 | 菲特法姆股份有限公司 | 皂角苷配基及其衍生物的用途 |
| US6933312B2 (en) | 2002-10-07 | 2005-08-23 | Agouron Pharmaceuticals, Inc. | Pyrazole derivatives |
| WO2004055201A2 (en) | 2002-12-13 | 2004-07-01 | Bayer Healthcare Ag | Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease |
| FR2850023B1 (fr) * | 2003-01-17 | 2007-04-06 | Mapreg | Medicaments pour le systeme nerveux |
| GB0403889D0 (en) | 2004-02-21 | 2004-03-24 | Univ Edinburgh | Uses of er-beta modulators |
| WO2006037016A2 (en) | 2004-09-27 | 2006-04-06 | The Regents Of The University Of California | Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| US20070032464A1 (en) | 2004-10-08 | 2007-02-08 | Shutsung Liao | Methods of treating cancers |
| WO2006050165A2 (en) | 2004-11-01 | 2006-05-11 | Seo Hong Yoo | Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis |
| CA2643732C (en) | 2006-02-27 | 2012-08-21 | The Regents Of The University Of California | Oxysterol compounds and the hedgehog pathway |
| EA200802167A1 (ru) * | 2006-04-22 | 2009-04-28 | Холлис-Эден Фармасьютикалс, Инк. | Лекарства и применения |
| CN101164540A (zh) | 2006-08-03 | 2008-04-23 | 中山大学 | 海洋甾体化合物在制备治疗神经元损伤药物中的应用 |
| GB0619860D0 (en) * | 2006-10-06 | 2006-11-15 | Birkeland Innovasjon As | Treatment of insulin resistance and disorders associated therewith |
| US8273747B2 (en) | 2006-11-02 | 2012-09-25 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| IN2014DN02014A (enExample) | 2006-11-21 | 2015-07-10 | Umecrine Ab | |
| KR101767849B1 (ko) | 2007-06-20 | 2017-08-11 | 오스펙스 파마슈티칼스, 인코포레이티드 | 섬유증 저해제로서의 치환된 ｎ-아릴 피리디논 |
| GB0712494D0 (en) | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
| WO2009059239A2 (en) * | 2007-11-02 | 2009-05-07 | Mayo Foundation For Medical Education And Research | REDUCING Aβ42 LEVELS AND Aβ AGGREGATION |
| JP2011502974A (ja) | 2007-11-06 | 2011-01-27 | ナームローゼ・フエンノートチヤツプ・オルガノン | ヒトにおけるホルモン抑制の方法 |
| US9526737B2 (en) | 2007-12-03 | 2016-12-27 | The Regents Of The University Of California | Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and Wnt signaling |
| WO2009090063A1 (en) | 2008-01-16 | 2009-07-23 | Jado Technologies Gmbh | Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases |
| US8273737B2 (en) | 2008-01-25 | 2012-09-25 | Merck Sharp & Dohme Corp. | Quinolizidinone M1 receptor positive allosteric modulators |
| JP2011520815A (ja) | 2008-05-09 | 2011-07-21 | エモリー・ユニバーシテイ | 精神神経障害治療のためのｎｍｄａ受容体拮抗薬 |
| WO2010065709A2 (en) | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
| WO2010075282A1 (en) | 2008-12-22 | 2010-07-01 | University Of Washington | Molecular inhibitors of the wnt/beta-catenin pathway |
| WO2010088414A2 (en) | 2009-01-28 | 2010-08-05 | Emory University | Subunit selective nmda receptor potentiators for the treatment of neurological conditions |
| US8829213B2 (en) | 2009-07-29 | 2014-09-09 | The University Of Chicago | Liver X receptor agonists |
| WO2011028794A2 (en) | 2009-09-01 | 2011-03-10 | Lazarus Therapeutics, Inc. | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist |
| FR2953138B1 (fr) | 2009-12-02 | 2015-10-16 | Assist Publ Hopitaux Marseille | Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus |
| WO2011092127A1 (en) | 2010-01-26 | 2011-08-04 | Bayer Schering Pharma Aktiengesellschaft | 14,17-bridged estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring |
| KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| US20120035156A1 (en) | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
| US8969525B2 (en) | 2010-11-09 | 2015-03-03 | Enzo Life Sciences, Inc. | Hydroxycholesterol immunoassay |
| US20150031655A1 (en) | 2011-04-15 | 2015-01-29 | University Of North Dakota | Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases |
| US20140335050A1 (en) | 2011-05-27 | 2014-11-13 | The General Hospital Corporation | Methods, compositions, and kits for the treatment of cancer |
| CA2843436A1 (en) | 2011-07-29 | 2013-02-07 | The Regents Of The University Of California | Novel 17.beta.-heteroaryl-substituted steroids as modulators of gaba a receptors |
| EP4245369A3 (en) | 2011-09-08 | 2023-11-22 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| AU2012323888A1 (en) | 2011-10-14 | 2014-05-29 | Sage Therapeutics, Inc. | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| US20150119327A1 (en) | 2012-04-25 | 2015-04-30 | The Regents Of The University Of California | Drug screening platform for rett syndrome |
| WO2014025942A1 (en) | 2012-08-09 | 2014-02-13 | Emory University | Nmda receptor modulators and uses related thereto |
| US20140149272A1 (en) | 2012-08-17 | 2014-05-29 | Trueex Group Llc | Interoffice bank offered rate financial product and implementation |
| JP6542127B2 (ja) | 2012-12-18 | 2019-07-10 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | 向神経活性１９−アルコキシ−１７−置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
| WO2014115167A2 (en) | 2013-01-23 | 2014-07-31 | Sphaera Pharma Pvt. Ltd. | Novel compounds of 11beta-hydroxy-steroids for use in mitochondria biogenesis and diseases associated with mitochondrial dysfunction or depletion |
| EA031905B1 (ru) | 2013-01-29 | 2019-03-29 | Аптиникс Инк. | Спиролактамные модуляторы рецептора nmda и их применение |
| MX362544B (es) | 2013-03-13 | 2019-01-24 | Sage Therapeutics Inc | Esteroides neuroactivos y metodos para su uso. |
| EP3865135A3 (en) | 2013-03-13 | 2021-11-03 | Sage Therapeutics, Inc. | Neuroactive steroids for use in therapy |
| WO2015120280A1 (en) | 2014-02-08 | 2015-08-13 | Genentech, Inc. | Methods of treating alzheimer's disease |
| JP6628745B2 (ja) | 2014-06-18 | 2020-01-15 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびその使用方法 |
| US10238664B2 (en) | 2014-07-09 | 2019-03-26 | Duke University | Compositions and methods for the repair of myelin |
| BR112017007053A2 (pt) | 2014-10-07 | 2018-06-19 | Sage Therapeutics Inc | compostos neuroativos e métodos de utilização deste composto. |
| SI3812392T1 (sl) | 2015-07-06 | 2025-09-30 | Sage Therapeutics, Inc. | Oksisteroli in postopki za uporabo le-teh |
| MA42410B1 (fr) | 2015-07-06 | 2021-04-30 | Sage Therapeutics Inc | Oxystérols et leurs méthodes d'utilisation |
| WO2017007832A1 (en) | 2015-07-06 | 2017-01-12 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| GB2557875A (en) | 2015-09-02 | 2018-07-04 | Univ Swansea | Diagnostic methods and kits |
| HUE059491T2 (hu) | 2016-04-01 | 2022-11-28 | Sage Therapeutics Inc | Oxiszterolok és azok alkalmazási eljárásai |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| PT3481846T (pt) | 2016-07-07 | 2021-08-13 | Sage Therapeutics Inc | 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda |
| WO2018013615A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| EP3519422B1 (en) | 2016-09-30 | 2022-08-31 | Sage Therapeutics, Inc. | C7 substituted oxysterols and these compounds for use as nmda modulators |
| EP4105223B1 (en) | 2016-10-18 | 2025-04-30 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| MA46566A (fr) | 2016-10-18 | 2019-08-28 | Sage Therapeutics Inc | Oxystérols et leurs procédés d'utilisation |
| ES3020935T3 (en) | 2017-03-15 | 2025-05-23 | Modernatx Inc | Lipid nanoparticle formulation |
| JP7224307B2 (ja) | 2017-06-23 | 2023-02-17 | インターセプト ファーマシューティカルズ， インコーポレイテッド | 胆汁酸誘導体の調製のための方法及び中間体 |
| JP7312169B2 (ja) | 2017-11-10 | 2023-07-20 | マリナス ファーマシューティカルズ インコーポレイテッド | 遺伝性てんかん性障害の処置に使用するガナキソロン |
| TWI855081B (zh) | 2019-05-24 | 2024-09-11 | 美商賽吉醫療公司 | 化合物、組合物及使用方法 |
-
2012
- 2012-09-07 EP EP23171488.2A patent/EP4245369A3/en active Pending
- 2012-09-07 CN CN202111105989.9A patent/CN113956315B/zh active Active
- 2012-09-07 CN CN201711063812.0A patent/CN107936076B/zh active Active
- 2012-09-07 HR HRP20230747TT patent/HRP20230747T1/hr unknown
- 2012-09-07 DK DK12766766.5T patent/DK2753632T3/da active
- 2012-09-07 AU AU2012304412A patent/AU2012304412A1/en not_active Abandoned
- 2012-09-07 BR BR112014005373-1A patent/BR112014005373B1/pt active IP Right Grant
- 2012-09-07 SM SM20230232T patent/SMT202300232T1/it unknown
- 2012-09-07 JP JP2014529913A patent/JP6205362B2/ja active Active
- 2012-09-07 US US14/343,603 patent/US20150158903A1/en not_active Abandoned
- 2012-09-07 CN CN201280054927.2A patent/CN103958540B/zh active Active
- 2012-09-07 HU HUE12766766A patent/HUE062616T2/hu unknown
- 2012-09-07 PT PT127667665T patent/PT2753632T/pt unknown
- 2012-09-07 RU RU2014113548A patent/RU2665571C2/ru active
- 2012-09-07 ES ES12766766T patent/ES2951664T3/es active Active
- 2012-09-07 EP EP12766766.5A patent/EP2753632B1/en active Active
- 2012-09-07 FI FIEP12766766.5T patent/FI2753632T3/fi active
- 2012-09-07 LT LTEPPCT/US2012/054261T patent/LT2753632T/lt unknown
- 2012-09-07 WO PCT/US2012/054261 patent/WO2013036835A1/en not_active Ceased
- 2012-09-07 CA CA2848212A patent/CA2848212C/en active Active
- 2012-09-07 PL PL12766766.5T patent/PL2753632T3/pl unknown
- 2012-09-07 CN CN202410996084.2A patent/CN119192267A/zh active Pending
- 2012-09-07 RS RS20230525A patent/RS64332B1/sr unknown
- 2012-09-07 SI SI201232034T patent/SI2753632T1/sl unknown
-
2017
- 2017-06-29 AU AU2017204452A patent/AU2017204452B2/en active Active
- 2017-09-04 JP JP2017169737A patent/JP2018021059A/ja not_active Withdrawn
-
2018
- 2018-08-28 US US16/114,791 patent/US10759828B2/en active Active
-
2019
- 2019-01-25 JP JP2019011169A patent/JP6777773B2/ja active Active
- 2019-09-10 AU AU2019227507A patent/AU2019227507B2/en active Active
-
2020
- 2020-07-29 US US16/942,235 patent/US20210147470A1/en not_active Abandoned
- 2020-10-08 JP JP2020170611A patent/JP2021008504A/ja not_active Withdrawn
-
2021
- 2021-06-21 AU AU2021204183A patent/AU2021204183B2/en active Active
-
2022
- 2022-03-29 US US17/707,303 patent/US12129275B2/en active Active
-
2023
- 2023-01-10 JP JP2023001738A patent/JP7786665B2/ja active Active
- 2023-05-15 AU AU2023203028A patent/AU2023203028B2/en active Active
-
2024
- 2024-09-23 US US18/893,387 patent/US20250257092A1/en active Pending
-
2025
- 2025-04-09 JP JP2025064398A patent/JP2025108535A/ja active Pending
- 2025-05-26 AU AU2025203873A patent/AU2025203873A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7786665B2 (ja) | 神経刺激性のステロイド、組成物、およびそれらの使用 | |
| JP7579639B2 (ja) | 神経刺激性ステロイド、組成物およびそれらの使用 | |
| HK40103457A (en) | Neuroactive steroids, compositions, and uses thereof | |
| HK40057477A (en) | Neuroactive steroids for use in therapy | |
| RU2808165C2 (ru) | Нейроактивные стероиды, композиции и их применения | |
| HK1200173B (en) | Neuroactive steroids, compositions, and uses thereof |